S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Modern Day Options Trading For Beginners! (Ad)pixel
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
BREAKING: Tiny biotech successfully treats blindness (Ad)
Judge rules online archive's book service violated copyright
Biden's moves on Alaska drilling, TikTok test young voters
BREAKING: Tiny biotech successfully treats blindness (Ad)
Ruling halts oil exports from Iraq's Kurdish area via Turkey
Finnish leadership condemns attack on veteran lawmaker
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Modern Day Options Trading For Beginners! (Ad)pixel
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
BREAKING: Tiny biotech successfully treats blindness (Ad)
Judge rules online archive's book service violated copyright
Biden's moves on Alaska drilling, TikTok test young voters
BREAKING: Tiny biotech successfully treats blindness (Ad)
Ruling halts oil exports from Iraq's Kurdish area via Turkey
Finnish leadership condemns attack on veteran lawmaker
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Modern Day Options Trading For Beginners! (Ad)pixel
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
BREAKING: Tiny biotech successfully treats blindness (Ad)
Judge rules online archive's book service violated copyright
Biden's moves on Alaska drilling, TikTok test young voters
BREAKING: Tiny biotech successfully treats blindness (Ad)
Ruling halts oil exports from Iraq's Kurdish area via Turkey
Finnish leadership condemns attack on veteran lawmaker
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Modern Day Options Trading For Beginners! (Ad)pixel
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
BREAKING: Tiny biotech successfully treats blindness (Ad)
Judge rules online archive's book service violated copyright
Biden's moves on Alaska drilling, TikTok test young voters
BREAKING: Tiny biotech successfully treats blindness (Ad)
Ruling halts oil exports from Iraq's Kurdish area via Turkey
Finnish leadership condemns attack on veteran lawmaker
NASDAQ:ACON

Aclarion - ACON Stock Forecast, Price & News

$0.83
+0.01 (+1.22%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.80
$0.83
50-Day Range
$0.55
$0.83
52-Week Range
$0.38
$4.05
Volume
12,923 shs
Average Volume
18,640 shs
Market Capitalization
$6.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Aclarion MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
261.4% Upside
$3.00 Price Target
Short Interest
Healthy
1.22% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$12,043 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars


ACON stock logo

About Aclarion (NASDAQ:ACON) Stock

Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.

Receive ACON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclarion and its competitors with MarketBeat's FREE daily newsletter.

ACON Stock News Headlines

Analyzing Aclarion (NASDAQ:ACON) & Progenity (NASDAQ:PROG)
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
Aclarion To Present at The LD Micro Main Event XV
See More Headlines
Receive ACON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclarion and its competitors with MarketBeat's FREE daily newsletter.

ACON Company Calendar

Today
3/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACON
Fax
N/A
Employees
3
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+261.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-7,610,000.00
Net Margins
-12,583.55%
Pretax Margin
-12,583.55%

Debt

Sales & Book Value

Annual Sales
$60,000.00
Book Value
$0.23 per share

Miscellaneous

Free Float
6,124,000
Market Cap
$6.52 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. Jeffrey John Thramann M.D. (Age 58)
    Exec. Chairman
    Comp: $300k
  • Mr. Brent Ness (Age 56)
    CEO, Pres & Director
    Comp: $339.6k
  • Mr. John Lorbiecki (Age 59)
    Chief Financial Officer
    Comp: $225k
  • Mr. Ryan Bond (Age 48)
    Chief Strategy Officer
    Comp: $202.6k













ACON Stock - Frequently Asked Questions

Should I buy or sell Aclarion stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aclarion in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACON shares.
View ACON analyst ratings
or view top-rated stocks.

What is Aclarion's stock price forecast for 2023?

1 Wall Street analysts have issued 1-year price targets for Aclarion's shares. Their ACON share price forecasts range from $3.00 to $3.00. On average, they predict the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 261.4% from the stock's current price.
View analysts price targets for ACON
or view top-rated stocks among Wall Street analysts.

How have ACON shares performed in 2023?

Aclarion's stock was trading at $0.58 on January 1st, 2023. Since then, ACON shares have increased by 43.1% and is now trading at $0.83.
View the best growth stocks for 2023 here
.

When did Aclarion IPO?

(ACON) raised $12 million in an IPO on Friday, April 22nd 2022. The company issued 2,165,000 shares at a price of $4.50-$6.50 per share.

What is Aclarion's stock symbol?

Aclarion trades on the NASDAQ under the ticker symbol "ACON."

How do I buy shares of Aclarion?

Shares of ACON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aclarion's stock price today?

One share of ACON stock can currently be purchased for approximately $0.83.

How much money does Aclarion make?

Aclarion (NASDAQ:ACON) has a market capitalization of $6.52 million and generates $60,000.00 in revenue each year.

How can I contact Aclarion?

Aclarion's mailing address is 951 MARINERS ISLAND BLVD STE 300, SAN MATEO CA, 94404. The official website for the company is www.aclarion.com. The company can be reached via phone at 833-275-2266.

This page (NASDAQ:ACON) was last updated on 3/26/2023 by MarketBeat.com Staff